Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
Acute disseminated encephalomyelitis (ADEM)
Antibodies
Cerebrospinal fluid
Encephalomyelitis
Lumbar puncture
MOG antibody-associated disease (MOGAD)
Multiple sclerosis (MS)
Myelin oligodendrocyte glycoprotein (MOG)
Neuromyelitis optica (Devic syndrome)
Oligoclonal bands
Optic neuritis
Transverse myelitis
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
03 Sep 2020
03 Sep 2020
Historique:
received:
08
11
2019
accepted:
23
04
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
22
7
2021
Statut:
epublish
Résumé
New-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD). To describe systematically the CSF profile in MOG-EM. Cytological and biochemical findings (including white cell counts and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively. Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis, blood-CSF barrier dysfunction was present also during remission in a substantial number of patients. MOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.
Sections du résumé
BACKGROUND
BACKGROUND
New-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD).
OBJECTIVE
OBJECTIVE
To describe systematically the CSF profile in MOG-EM.
MATERIAL AND METHODS
METHODS
Cytological and biochemical findings (including white cell counts and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively.
RESULTS
RESULTS
Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis, blood-CSF barrier dysfunction was present also during remission in a substantial number of patients.
CONCLUSION
CONCLUSIONS
MOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.
Identifiants
pubmed: 32883348
doi: 10.1186/s12974-020-01824-2
pii: 10.1186/s12974-020-01824-2
pmc: PMC7470615
doi:
Substances chimiques
Autoantibodies
0
Immunoglobulins
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
261Subventions
Organisme : Dietmar Hopp Stiftung
ID : n/a
Organisme : Merck Serono Germany
ID : n/a
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : n/a
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : n/a
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : n/a
Organisme : Deutsche Forschungsgemeinschaft (DFG Exc 257)
ID : n/a
Organisme : Deutsche Forschungsgemeinschaft
ID : n/a
Organisme : Baden-Württemberg Ministry of Science, Research and the Arts
ID : n/a
Organisme : Ruprecht-Karls-Universität Heidelberg
ID : n/a
Organisme : Jubilaeumsfonds of the Austrian National Bank
ID : 14158 and 15918
Références
Int J Mol Sci. 2016 Sep 21;17(9):
pubmed: 27657060
Neurology. 1999 Sep 22;53(5):1107-14
pubmed: 10496275
J Neuroinflammation. 2013 Jan 15;10:8
pubmed: 23320783
Mult Scler. 2009 Dec;15(12):1466-80
pubmed: 19995844
Ann Neurol. 2006 Mar;59(3):566-9
pubmed: 16453327
J Neuroinflammation. 2016 Nov 1;13(1):282
pubmed: 27802824
Arthritis Rheum. 2010 Apr;62(4):1198-200
pubmed: 20131265
J Neuroinflammation. 2019 Dec 28;16(1):280
pubmed: 31883522
J Neuroinflammation. 2012 Jan 19;9:14
pubmed: 22260418
Dtsch Med Wochenschr. 1979 Apr 13;104(15):553-7
pubmed: 436627
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
Neurology. 2004 Dec 28;63(12):2363-70
pubmed: 15623701
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e231
pubmed: 27144221
J Neurol Sci. 1994 Apr;122(2):189-203
pubmed: 8021703
J Neurol Sci. 2019 Dec 15;407:116396
pubmed: 31726278
Nervenarzt. 2018 Dec;89(12):1388-1399
pubmed: 30264269
Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083
pubmed: 29623106
Clin Chem Lab Med. 2010 May;48(5):659-63
pubmed: 20184532
J Neuroinflammation. 2018 Jan 18;15(1):22
pubmed: 29347989
Brain. 2008 Nov;131(Pt 11):3072-80
pubmed: 18945724
J Neurol. 2017 Mar;264(3):453-466
pubmed: 28005176
J Exp Med. 1986 Jan 1;163(1):41-53
pubmed: 3941297
J Neuroinflammation. 2016 Nov 1;13(1):281
pubmed: 27802825
Front Neurol. 2018 Oct 23;9:888
pubmed: 30405519
Acta Neurol Scand. 1988 Jul;78(1):6-9
pubmed: 3176884
Clin Exp Immunol. 2014 May;176(2):149-64
pubmed: 24666204
J Gen Physiol. 1992 Aug;100(2):341-67
pubmed: 1402785
Med Hypotheses. 2013 Dec;81(6):1090-5
pubmed: 24182872
Neurosci Lett. 1988 Apr 12;86(3):296-300
pubmed: 3380321
Brain. 2007 May;130(Pt 5):1235-43
pubmed: 17449477
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Arch Neurol. 1967 May;16(5):492-6
pubmed: 6022530
Brain. 2002 Jul;125(Pt 7):1450-61
pubmed: 12076996
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62
pubmed: 25635259
Arch Neurol. 2007 Dec;64(12):1802; author reply 1802-3
pubmed: 18071052
Curr Opin Neurol. 2017 Jun;30(3):295-301
pubmed: 28248700
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
pubmed: 27458601
Am J Med. 1995 Aug;99(2):153-63
pubmed: 7625420
J Exp Med. 2008 Oct 27;205(11):2473-81
pubmed: 18838545
Mult Scler. 2016 Oct;22(12):1541-1549
pubmed: 26869529
Arch Intern Med. 1983 Jan;143(1):85-7
pubmed: 6849611
Mult Scler. 2015 Jun;21(7):866-874
pubmed: 25344373
Glia. 1988;1(6):366-70
pubmed: 2976396
J Neuroinflammation. 2018 Mar 19;15(1):88
pubmed: 29554927
J Neuroinflammation. 2017 Aug 29;14(1):171
pubmed: 28851393
JAMA Neurol. 2014 Mar;71(3):276-83
pubmed: 24425068
J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1134-6
pubmed: 18270237
Arch Neurol. 2007 Jun;64(6):899-901
pubmed: 17562942
Mult Scler. 2012 Jan;18(1):5-10
pubmed: 22146604
Neurology. 2012 Sep 18;79(12):1273-7
pubmed: 22914827
J Neuroinflammation. 2011 Dec 28;8:184
pubmed: 22204662
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
JAMA Neurol. 2018 Jan 1;75(1):65-71
pubmed: 29131884
Cerebrospinal Fluid Res. 2005 Jun 27;2:3
pubmed: 15982411
J Cereb Blood Flow Metab. 1989 Jun;9(3):381-7
pubmed: 2497112
Arch Neurol. 2007 Jun;64(6):901-3
pubmed: 17562943
Mult Scler. 1998 Jun;4(3):111-7
pubmed: 9762657
Autoimmun Rev. 2016 Apr;15(4):307-24
pubmed: 26708342
Neurology. 2006 May 23;66(10):1485-9
pubmed: 16717206
J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):446-51
pubmed: 9343121
Arch Neurol. 2007 Jun;64(6):906
pubmed: 17562945
Ann Neurol. 2018 Aug;84(2):315-328
pubmed: 30014603
Medicine (Baltimore). 2004 Sep;83(5):280-91
pubmed: 15342972
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Arch Neurol. 2010 Oct;67(10):1201-8
pubmed: 20937947
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
J Neurol Sci. 2009 May 15;280(1-2):98-100
pubmed: 19041103
J Neurol Sci. 2011 Jul 15;306(1-2):82-90
pubmed: 21550068
Lancet Neurol. 2016 Mar;15(3):317-31
pubmed: 26724102
J Neurosci. 2006 Mar 22;26(12):3220-8
pubmed: 16554473
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neuroinflammation. 2010 Sep 08;7:52
pubmed: 20825655
J Neuroinflammation. 2019 Feb 28;16(1):51
pubmed: 30819213
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902
pubmed: 8057110
Mult Scler. 2011 Sep;17(9):1067-73
pubmed: 21543553
J Neurol. 2016 Jul;263(7):1349-60
pubmed: 27147513